NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma

Osteosarcoma(OS) remains a major health concern in childhood and adolescence, although cisplatin is one of the gold standard chemotherapeutic drugs in the treatment of OS, chemoresistant to cisplatin is common. Phosphoinositide 3-kinase (PI3K)-Akt-mammalian target of rapamycin inhibitor (mTOR) pathw...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Huang, Jin-Cheng, Cui, Zhi-Fei, Chen, Shui-Mu, Yang, Lian-Jun, Lian, Hong-Kai, Liu, Bin, Su, Zhi-Hai, Liu, Jin-Shi, Wang, Min, Hu, Zheng-Bo, Ouyang, Jia-Yao, Li, Qing-Chu, Lu, Hai
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5828183/
https://ncbi.nlm.nih.gov/pubmed/29535821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23711
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items